Ensysce Biosciences Stock Today

ENSC Stock  USD 0.55  0.01  0.91%   


0 of 100

Very Weak

Odds Of Distress

Over 84

Very High
Ensysce Biosciences is trading at 0.545 as of the 21st of June 2024, a -0.91 percent decrease since the beginning of the trading day. The stock's open price was 0.55. Ensysce Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Ensysce Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of May 2024 and ending today, the 21st of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
26th of February 2018
Health Care
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company has 7.59 M outstanding shares of which 193.16 K shares are currently shorted by private and institutional investors with about 1.01 trading days to cover. More on Ensysce Biosciences

Moving together with Ensysce Stock

  0.72VYGR Voyager TherapeuticsPairCorr
  0.73EGRX Eagle PharmaceuticalsPairCorr

Moving against Ensysce Stock

  0.38MRK Merck Company Financial Report 6th of August 2024 PairCorr
  0.33LLY Eli LillyPairCorr

Ensysce Stock Highlights

CEO PresidentLynn Kirkpatrick
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.780.8237
Notably Down
Pretty Stable
Total Current Liabilities6.2 M3.3 M
Way Up
Slightly volatile
Non Current Liabilities Total25.1 K26.4 K
Notably Down
Slightly volatile
Total Assets2.6 M2.7 M
Notably Down
Slightly volatile
Total Current Assets2.2 M2.3 M
Notably Down
Slightly volatile
Ensysce Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ensysce Biosciences' financial leverage. It provides some insight into what part of Ensysce Biosciences' total assets is financed by creditors.
Ensysce Biosciences currently holds 854.7 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity.

Change In Cash

(1.92 Million)
Ensysce Biosciences (ENSC) is traded on NASDAQ Exchange in USA. It is located in 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037 and employs 7 people. Ensysce Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.19 M. Ensysce Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 7.59 M outstanding shares of which 193.16 K shares are currently shorted by private and institutional investors with about 1.01 trading days to cover. Ensysce Biosciences currently holds about 3.15 M in cash with (10.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Check Ensysce Biosciences Probability Of Bankruptcy
Ownership Allocation
Roughly 93.0 percent of Ensysce Biosciences outstanding shares are held by general public with 2.3 (percent) owned by insiders and only 4.21 % by other corporate entities.
Check Ensysce Ownership Details

Ensysce Stock Institutional Holders

InstituionRecorded OnShares
Vanguard Group Inc2024-03-31
18.2 K
Bank Of America Corp2023-12-31
Geode Capital Management, Llc2023-12-31
16.3 K
Renaissance Technologies Corp2023-12-31
11 K
Tower Research Capital Llc2023-12-31
6.3 K
Blackrock Inc2023-12-31
Main Street Group Ltd2024-03-31
Wells Fargo & Co2023-12-31
Ubs Group Ag2023-12-31
Sabby Management Llc2023-12-31
Wolverine Asset Management Llc2023-12-31
View Ensysce Biosciences Diagnostics

Ensysce Biosciences Historical Income Statement

At present, Ensysce Biosciences' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 96.5 K, whereas Interest Income is forecasted to decline to about 93.6 K. View More Fundamentals

Ensysce Stock Against Markets

Ensysce Biosciences Corporate Management

Additional Information and Resources on Investing in Ensysce Stock

When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.